权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bone marrow transplant clinical network

骨髓移植临床网络

基本信息

批准号：
7479234
负责人：
EDWARD A STADTMAUER
金额：
$ 15.05万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
起止时间：
2001-09-30 至 2011-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7479234
关键词：
Age Allogenic Appendix Applications Grants Blood Bone Marrow Bone Marrow Transplantation Caring Certification Child Clinical Clinical Practice Guideline Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Collection Commit Conduct Clinical Trials Conflict of Interest Data Coordinating Center Deficiency Diseases Depth Development Disease Effectiveness Ensure Failure Focus Groups Goals HLA Antigens Heart Hematopoietic Stem Cell Transplantation Hospitals Human Resources Human Subject Research Immune Individual Informed Consent Institutes Letters Lung Malignant - descriptor Malignant Neoplasms Marrow Measures Methods Minnesota Morbidity - disease rate Multicenter Studies National Cancer Institute Non-Malignant Numbers Nursing Faculty Office for Human Research Protections Outcome Patient Selection Patients Pennsylvania Physicians Policies Principal Investigator Procedures Protocols documentation Randomized Clinical Trials Randomized Controlled Clinical Trials Regulation Research Research Ethics Committees Research Personnel Research Subjects Risk Siblings Source Staging Stem cells Supportive care Techniques Testing Time Training Transplantation Treatment Protocols United States United States Food and Drug Administration Universities Update Work abstracting base cancer therapy human subject improved medical schools member mortality novel patient oriented research programs

项目摘要

DESCRIPTION (provided by applicant): The first successful hematopoietic stem cell transplantations (HCT) were done in 1968 in three children with congenital immune deficiency diseases. In each instance, stem cells were collected from the bone marrow of sibling donors who were genotypically identical or closely matched to the recipient for human leukocyte antigens (HLA). Since then, thousands of HCTs have been performed to treat malignant and non-malignant diseases. Current estimates of annual numbers of HCTs are about 45,000 worldwide, with 15-20,000 annually in the United State. Reasons for increasing use include proven and potential efficacy in many diseases, better understanding of the appropriate timing of transplantation and patient selection, greater availability of donors and better techniques for determining HLA match, greater ease of stem cell collection, and improved supportive care resulting in less transplant-related mortality. Despite these improvements, application of HCT is still limited by relatively high risks of morbidity and mortality and, in the case of allogeneic HCT, availability of suitable donors. HCT outcomes are influenced by many patient- and disease-related factors such as age, disease stage and prior treatment, as well as transplant-related factors such as stem cell source and transplant regimen. Ideally, the effectiveness of most transplant strategies would be evaluated in large randomized clinical trials. However, various factors hamper the ability to conduct randomized trials in this setting. Many diseases treated with HCT are uncommon. Additionally, for allogeneic transplants, not all patients have a suitable donor identified. Consequently, even when one considers the most common indications for HCT, numbers of eligible patients in individual centers are small. The ability to test new transplant strategies in a definitive way requires the existence of a network committed to development and implementation of large, multicenter studies. Under RFA HL-01-004, the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) jointly established a Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The goal of the Network is to efficiently assess novel HCT methods and management strategies derived from single center studies in a multi-center setting. The focus of this group, in contrast to cancer clinical trials groups, is on improving the transplant procedure per se rather than cancer treatment in general. (End of abstract.)

描述（由申请人提供）：